Global recognition for the TGA.
PBS tensions escalating into legal action.
And major leadership shifts across pharma.

In this episode, Tim Boyle breaks down the three biggest stories shaping Australia’s life sciences sector this week — and why they matter for regulatory affairs, market access, clinical research and pharma professionals.

What does WHO recognition mean for the TGA’s global influence?
Is PBS policy entering a new phase of tension?
And what do executive changes signal about sector recalibration?

If you work in medtech, pharma or biotech, this is your weekly sector briefing.